Canakinumab

File:Canakinumab bound to IL-1β.png

Ribbon diagram of canakinumab (blue) bound to IL-1β (yellow) from PDB entry 5bvp

Canakinumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IL-1β
Clinical data
Trade names	Ilaris
AHFS/Drugs.com	Consumer Drug Information
Licence data	EMA:Link, US FDA:link
Legal status	US: ℞-only
Routes of administration	intravenous, subcutaneous
Identifiers
CAS Number	914613-48-2 N
ATC code	L04AC08 (WHO)
DrugBank	DB06168 Y
UNII	37CQ2C7X93 Y
ChEMBL	CHEMBL1201834 N
Chemical data
Formula	C6452H9958N1722O2010S42
Molecular mass	145.2 kg/mol
NY (what is this?)  (verify)

Canakinumab (INN, trade name Ilaris, previously ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.

Canakinumab was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS) by the U.S. Food and Drug Administration (FDA) on June 2009 and by the European Medicines Agency in October 2009. CAPS is a spectrum of autoinflammatory syndromes including familial cold autoinflammatory syndrome, Muckle–Wells syndrome, and neonatal-onset multisystem inflammatory disease.

Canakinumab was being developed by Novartis for the treatment of rheumatoid arthritis but this trial was completed in October 2009. Canakinumab is also in phase I clinical trials as a possible treatment for chronic obstructive pulmonary disease, gout and coronary artery disease. It is also in trials for Schizophrenia. In gout it may result in better outcomes than a low dose of a steroid but costs five thousand times more.